Stocks
Inhibikase Therapeutics, Inc.IKT
NASDAQHealthcareBiotechnology$1.81
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing kinase inhibitor therapies for rare and orphan diseases, with a lead candidate targeting Parkinson's disease and other neurodegenerative conditions. Its pipeline also includes treatments for pulmonary arterial hypertension, and investors track the stock for its progress in Phase 2 and Phase 3 trials.
52W Range: $1.33-$2.61
Congressional Interest in Inhibikase Therapeutics, Inc. (IKT)
No congressional trades have been disclosed for Inhibikase Therapeutics, Inc. (IKT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading IKT?
No congressional trades found for this stock.